Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

An oncolytic mutant of herpes simplex virus type-1 in which replication is governed by a promoter/enhancer of human papillomavirus type-16

Cancer Gene Therapy volume 14, pages 985–993 (2007)Cite this article

Abstract

Although herpes simplex virus type-1 (HSV-1) can be used as an oncolytic virus it has the undesirable side effect of neurotoxicity. To create a virus with improved specificity for oral cancer we used a fragment of human papillomavirus type-16, which is frequently found in oral and cervical cancers, but not elsewhere. The upstream regulatory region, URR16, was shown to have a high level of transcriptional activity in three of four oral cancer cell lines but low activity in three cell lines derived from brain cancers. URR16 was therefore placed in HSV-1, replacing the promoter of the essential gene ICP4, and the resulting virus was named HSPV-1. When cells were infected with HSPV-1, ICP4 was expressed at levels that were not associated with the level of activity of URR16. The virus replicated in each type of cell to a final titer that showed a correlation with the level of expression of ICP4, but with no correlation to either the tumor of origin or the presence of HPV sequences in the cells. To find if some function of HSV-1 was affecting the activity of URR16, oral cancer cells were transfected with a URR-reporter construct and were then infected with virus. This induced transcription, which was attributed to immediate-early viral genes other than ICP4. A promoter/enhancer from a papillomavirus therefore has the potential to regulate the functions of an oncolytic strain of HSV-1, and is affected by functions of both the host cell and of HSV-1 itself.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9

Similar content being viewed by others

Accession codes

Accessions

GenBank/EMBL/DDBJ

References

  1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A et al. Cancer statistics 2005. CA Cancer J Clin 2005; 55: 10–30.

    Article  PubMed  Google Scholar 

  2. Miller C, Johnstone B . Human papillomavirus as a risk factor for oral squamous cell carcinoma: a meta-analysis, 1982–1997. Oral Surg Med Pathol Radiol Endo 2001; 91: 622–635.

    Article  CAS  Google Scholar 

  3. Ringstrom E, Peters E, Hasegawa M, Posner M, Liu M, Kelsey KT . Human papillomavirus type 16 and squamous cell carcinoma of the head and neck. Clin Cancer Res 2002; 8: 3187–3192.

    PubMed  Google Scholar 

  4. Corey L . Herpes simplex viruses. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL (eds). Harrison's Principles of Internal Medicine, 15th edn. McGraw-Hill: New York, 2001. pp 1100–1106.

    Google Scholar 

  5. Lou E, Kellman RM, Shillitoe EJ . Effect of herpes simplex virus type-1 on growth of oral cancer in an immunocompetent, orthotopic mouse model. Oral Oncol 2002; 38: 349–356.

    Article  CAS  PubMed  Google Scholar 

  6. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL . Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995; 1: 938–943.

    Article  CAS  PubMed  Google Scholar 

  7. Markert JM, Medlock M, Rabkin SD, Gillespie GY, Todo T, Hunter WD et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Therapy 2000; 7: 867–874.

    Article  CAS  PubMed  Google Scholar 

  8. Carew JF, Kooby DA, Halterman MW, Federoff HJ, Fong Y . Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus Type-1 (G207). Hum Gen Ther 1999; 10: 1599–1606.

    Article  CAS  Google Scholar 

  9. Chahlavi A, Todo T, Martuza RL, Rabkin SD . Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia 1999; 1: 162–169.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Kim SH, Wong RJ, Kooby DA, Carew JF, Adusumilli PS, Patel SG et al. Combination of mutated herpes simplex virus type 1 (G207 virus) with radiation for the treatment of squamous cell carcinoma of the head and neck. Eur J Cancer 2005; 41: 313–322.

    Article  CAS  PubMed  Google Scholar 

  11. Miyatake S, Iyer A, Martuza RL, Rabkin SD . Transcriptional targeting of herpes simplex virus for cell-specific replication. J Virol 1997; 71: 5124–5132.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Chung RY, Saeki Y, Chiocca EA . B-myb promoter retargeting of herpes simplex virus gamma-34.5 gene-mediated virulence toward tumor and cycling cells. J Virol 1999; 73: 7556–7564.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Kasuya H, Pawlik T, Mullen J, Donahue J, Nakamura H, Chandrasekhar S et al. Selectivity of an oncolytic herpes simplex virus for cells expressing the DF3/MUC1 antigen. Cancer Res 2004; 64: 2561–2567.

    Article  CAS  PubMed  Google Scholar 

  14. Yamamura H, Hashio M, Noguchi M, Sugenoya Y, Asakada M, Hirano N et al. Identification of the transcriptional regulatory sequences of human calponin promoter and their use in targeting a conditionally replicating herpes vector to malignant human soft tissue and bone tumors. Cancer Res 2001; 61: 3969–3977.

    CAS  PubMed  Google Scholar 

  15. Kuroda T, Rabkin SD, Martuza RL . Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector. Cancer Res 2006; 66: 10127–10135.

    Article  CAS  PubMed  Google Scholar 

  16. Gloss B, Bernard HU, Seedorf K, Klock G . The upstream regulatory region of the human papilloma virus-16 contains an E2 protein-independent enhancer which is specific for cervical carcinoma cells and regulated by glucocorticoid hormones. EMBO J 1987; 6: 3735–3743.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Cripe TP, Haugen TH, Turk JP, Tabatabai F, Schmid PG, Durst M et al. Transcriptional regulation of the human papillomavirus-16 E6-E7 promoter by a keratinocyte-dependent enhancer, and by viral E2 trans-activator and repressor gene products: implications for cervical carcinogenesis. EMBO J 1987; 6: 3745–3753.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Shillitoe EJ, Noonan S . Strength and specificity of different gene promoters in oral cancer cells. Oral Oncol 2000; 36: 214–220.

    Article  CAS  PubMed  Google Scholar 

  19. Chen Z, Storthz KA, Shillitoe EJ . Mutations in the long control region of human papillomavirus DNA in oral cancer cells, and their functional consequences. Cancer Res 1997; 57: 1614–1619.

    CAS  PubMed  Google Scholar 

  20. Gibson SA, Pellenz C, Hutchison RE, Davey F, Shillitoe EJ . Induction of apoptosis in oral cancer cells by an anti-bcl-2 ribozyme delivered by an adenovirus vector. Clin Cancer Res 2000; 6: 213–222.

    CAS  PubMed  Google Scholar 

  21. Shillitoe EJ, Gilchrist E, Pellenz C, Murrah V . Effects of herpes simplex virus on human oral cancer cells, and potential use of mutant viruses in therapy of oral cancer. Oral Oncol 1999; 35: 326–332.

    Article  CAS  PubMed  Google Scholar 

  22. Kooby DA, Carew JF, Halterman MW, Mack J, Bertino J, Blumgart L et al. Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). FASEB J 1999; 13: 1325–1334.

    Article  CAS  PubMed  Google Scholar 

  23. Kotelnikov VM, Coon JS, Mundle S, Kelanic S, LaFolette S, Taylor S et al. Cyclin D1 expression in squamous cell carcinomas of the head and neck and in oral mucosa in relation to proliferation and apoptosis. Clin Cancer Res 1997; 3: 95–101.

    CAS  PubMed  Google Scholar 

  24. Oya R, Ikemura K . Can flow cytometrically determined DNA ploidy and S-phase fraction predict regional metastasis in squamous cell carcinoma of the oral cavity? Head and Neck 2002; 24: 136–142.

    Article  PubMed  Google Scholar 

  25. Preston CM . Abnormal properties of an immediate early polypeptide in cells infected with the herpes simplex virus type 1 mutant tsK. J Virol 1979; 32: 357–369.

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Mullen JT, Kasuya H, Yoon SS, Carroll NM, Pawlik TM, Chandrasekhar S et al. Regulation of herpes simplex virus type 1 replication using tumor-associated promoters. Annal Surg 2002; 236: 502–513.

    Article  Google Scholar 

  27. Apt D, Watts RM, Suske G, Bernard HU . High Sp1/Sp3 ratios in epithelial cells during epithelial differentiation and cellular transformation correlate with the activation of the HPV-16 promoter. Virology 1996; 224: 281–291.

    Article  CAS  PubMed  Google Scholar 

  28. O'Connor M, Stunkel W, Koh CH, Zimmerman H, Bernard HU . The differentiation-specific factor CDP/Cut represses transcription and replication of human papillomaviruses through a conserved silencing element. J Virol 2000; 74: 401–410.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Rixon FJ, McGeoch DJ . Detailed analysis of the mRNAs mapping in the short unique region of herpes simplex virus type 1. Nucl Acids Res 1985; 13: 953–973.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. DeLuca NA, Schaffer PA . Physical and functional domains of the herpes simplex virus transcriptional regulatory protein ICP4. J Virol 1988; 62: 732–743.

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Hara Y, Kimoto T, Okuno Y, Minekawa Y . Effect of herpes simplex virus on the DNA of human papillomavirus 18. J Med Virol 1997; 53: 4–12.

    Article  CAS  PubMed  Google Scholar 

  32. Fang L, Ward MG, Welsh PA, Budgeon LR, Neely EB, Howett MK . Suppression of human papillomavirus gene expression in vitro and in vivo by herpes simplex virus type 2 infection. Virology 2003; 314: 147–160.

    Article  CAS  PubMed  Google Scholar 

  33. Meyers C, Andreansky SS, Courtney RJ . Replication and interaction of herpes simplex virus and human papillomavirus in differentiating host epithelial tissue. Virology 2003; 315: 43–55.

    Article  CAS  PubMed  Google Scholar 

  34. McCusker CT, Bacchetti S . The responsiveness of human papillomavirus upstream regulatory regions to herpes simplex virus immediate early proteins. Virus Res 1988; 11: 199–207.

    Article  CAS  PubMed  Google Scholar 

  35. Pollara G, Jones M, Handley ME, Rajpopat M, Kwan A, Coffin RS et al. Herpes simplex virus type-1-induced activation of myeloid dendritic cells: the roles of virus cell interaction and paracrine type I IFN secretion. J Immunol 2004; 173: 4108–4119.

    Article  CAS  PubMed  Google Scholar 

  36. DeLuca N, McCarthy A, Schaffer P . Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4. J Virol 1985; 56: 558–570.

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Gius D, Laimins LA . Activation of human papillomavirus type 18 gene expression by herpes simplex virus type 1 viral trans-activators and a phorbol ester. J Virol 1989; 63: 555–563.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This study was supported by NIH Grant R01DE13214 and by the Carol A Baldwin Cancer Research Foundation. We thank Dr SD Rabkin for his valuable advice.

Author information

Authors and Affiliations

  1. Department of Microbiology and Immunology, SUNY Upstate Medical University, Syracuse, NY, USA

    C Griffith, S Noonan, E Lou & E J Shillitoe

Authors
  1. C Griffith
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Noonan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E Lou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E J Shillitoe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E J Shillitoe.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Griffith, C., Noonan, S., Lou, E. et al. An oncolytic mutant of herpes simplex virus type-1 in which replication is governed by a promoter/enhancer of human papillomavirus type-16. Cancer Gene Ther 14, 985–993 (2007). https://doi.org/10.1038/sj.cgt.7701089

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.cgt.7701089

Keywords

This article is cited by

Search

Advanced search

Quick links